Knee Osteoarthritis. Erosive (osteo)arthritis
Conditions
Interventions
Intervention group: Patients with knee arthritis receiving platelet lysate and platelet-rich plasma.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Men and women between the ages of 18 and 75 with OA diagnosis based on the American College of Rheumatology Analog scale of knee pain (VAS) equal to or greater than 2.5 People with at least 4 months of history of pain or swelling in one or both knees Radiological classification scale Kellgren-Lawrence 1 or 2 The availability of individual during the study period BMI Between 20 and 35
Exclusion criteria
Exclusion criteria: People under the age of 18 and over 75 years Pregnant women or women who are breastfeeding People with malignancy,People with severe heart disease, uncontrolled diabetes mellitus, rheumatoid arthritis, hemorrhagic diseases, history of anemia, arthritis, fibromyalgia and chronic fatigue syndrome Those linked to acetaminophen or Vicodin or a history of drug misuse History of cortisone injections in the last 6 weeks The use of non-steroidal anti-inflammatory drugs 1 week ago Having hemoglobin less than 11 g / dl and platelet count less than 150000 / mµ The use of inhibitors of platelet aggregation and anti-coagulation such as heparin History of knee surgery in the last 3 months Extraordinary deformation (varus >5?, valgus >5?)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determining knee pain by VAS in all phases of clinical trial. Timepoint: 1 and 6 months after the first injection. Method of measurement: Questionnaire (Visual Analogue Scale).;Determination of knee function by Western Ontario and McMaster Universities Osteoarthritis Index in all phases of clinical trial. Timepoint: 1 and 6 months after the first injection. Method of measurement: Questionnaire (Western Ontario and McMaster Universities Osteoarthritis Index).;Determine the range of knee motion by manual joiniometry in all phases of clinical trial. Timepoint: 1 and 6 months after the first injection. Method of measurement: Range of motion (Degree).;Measurement of growth factors in platelet lysate and Platelet-rich plasma. Timepoint: 1 and 6 months after the first injection. Method of measurement: Elisa. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determine the thickness of the knee cartilage. Timepoint: 6 months after the first injection. Method of measurement: MRI. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehdi Yousefi
Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Outcome results
None listed